Zimbabwean Government to Delay enrollment of additional HIV-positive people in drug treatment program

The Zimbabwean government has announced that it will postpone enrolling additional HIV-positive people to its antiretroviral treatment program following reports that its drug supply could run out by December, PlusNews reports.

According to Health Minister David Parirenyatwa, the government is able to continue providing antiretrovirals to people currently on the treatment program, but it does not have the resources to add more people to the program.

Zimbabwe is experiencing a "severe economic crisis" because of recurring droughts and the government's land redistribution program, both of which have interrupted agricultural production and harmed export earnings, PlusNews reports.

The government in 2002 declared a state of emergency in response to the HIV/AIDS epidemic, which allows the country to import and locally manufacture less-expensive generic drugs under World Trade Organization regulations.

However, the country's drug manufacturer, Varichem, has been constrained by a lack of foreign currency to import raw materials to make antiretrovirals, according to PlusNews.

About 42,000 HIV-positive people are receiving antiretrovirals from state programs, and about 310,000 people need the drugs, PlusNews reports.

Mary Sandasi, executive director of the Women and AIDS Support Network, said the government is "sentencing to death" thousands of people living with the virus. Benjamin Mazhindu, Zimbabwe National Network for People Living with HIV and AIDS chair, said the organization hopes to meet with Parirenyatwa this week to address the shortage.

Some HIV-positive Zimbabweans have said that they will stage protests if the government fails to provide increased access to antiretrovirals, PlusNews reports (PlusNews, 10/18).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New hepatitis B vaccine offers superior protection for people with HIV